NCT02279875View on ClinicalTrials.gov

A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)

PHASE2CompletedINTERVENTIONAL

Enrollment

113

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 28, 2016

Study Completion Date

July 31, 2017

Conditions

Pulmonary Tuberculosis

Interventions

DRUG

Linezolid

DRUG

HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)

isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg

Trial Locations (2)

7530

TASK Clinical Research Centre, Bellville

7700

University of Cape Town Lung Institute (Pty) Ltd, Mowbray

All Listed Sponsors

lead

Global Alliance for TB Drug Development

OTHER

NCT02279875 - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) | Biotech Hunter | Biotech Hunter